… Aucamp, J. du Plessis and M Gerber contributed to planning the project and critical reviewing
of the manuscript. All authors contributed to the final manuscript as it was submitted to the …

… J du Plessis has 30 years’ experience in topical and transdermal drug delivery which …
LH du Plessis is a molecular biologist. She has vast experience in in vitro efficacy testing of …

It has been recognized that the vehicle in which a permeant is applied to the skin has a
distinctive effect on the dermal and transdermal delivery of active ingredients. The cutaneous and …

Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

… 1 Jean J du Plessis, ‘Corporate law and corporate governance lessons from the past: Ebbs
… 3 Du Plessis, ‘Corporate law and corporate governance lessons from the past’ 43. See also …

… Since its first introduction, Du Plessis and co-workers have formulated several characteristics
for the application of an RUC (Du Plessis 1989, Du Plessis 1991a, Du Plessis 1991b; Du …

Background & Aims The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased
with the obesity pandemic. We analyzed the transcriptional profiles of subcutaneous …

It is a significant though wholly undesigned coincidence that the completion of this" History,"
which has occupied the author's leisure hours during the past three years, should …

A new mathematical model is proposed for time-independent laminar flow through a rigid
isotropic and consolidated porous medium of spatially varying porosity. The model is based …

Tuberculosis is one of the oldest diseases known to humankind and it is currently a worldwide
threat with 8–9 million new active disease being reported every year. Among patients with …